Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
SNY US​

Sanofi American Depositary Receipt(SNY US)

$41.60-0.360.86%Ext:$41.68+0.080.19%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Sanofi American Depositary Receipt — Company Profile

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Belén Garijo López
Headquarters
Paris, I0, FR
IPO Date
Jul 1, 2002
Employees
76,493
Website
www.sanofi.com

Key Metrics

Price
$39.92
Market Cap
$95.86B
Revenue (TTM)
$11.24B
Net Income (TTM)
$1.61B
EPS (TTM)
0.67
P/E (TTM)
12.69
P/B (TTM)
1.32
Dividend Yield
5.58%
ROE (TTM)
10.95%
ROA (TTM)
6.16%
Operating Margin
20.54%
Beta
0.28

Dividends

Last Dividend
$2.42
Last Yield
0.06%

Summary

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Website
www.sanofi.com
Location
Paris, I0, FR
Phone33 1 53 77 40 00
Employees76,493
CEOBelén Garijo López
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJul 1, 2002

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1.5K)

Expand
  • 6-KCurrent report (foreign private issuer)1 Oct
  • 6-KCurrent report (foreign private issuer)17 Sep
  • N-PXAnnual report of proxy voting record25 Aug
  • 4Statement of changes in beneficial ownership12 Aug
  • 3Initial statement of beneficial ownership12 Aug
  • 4Statement of changes in beneficial ownership7 Aug
  • 6-KCurrent report (foreign private issuer)6 Aug
  • 3Initial statement of beneficial ownership4 Aug
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 13F-HRQuarterly report (institutional investment manager holdings)28 Jul
  • 6-KCurrent report (foreign private issuer)27 Jul
  • SC 13G/ASanofi22 Jul
  • 6-KCurrent report (foreign private issuer)17 Jul
  • 6-KCurrent report (foreign private issuer)7 Jul
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)30 Jun
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)30 Jun
  • NT 11-KNT 11-K30 Jun
  • NT 11-KNT 11-K30 Jun
  • 6-KCurrent report (foreign private issuer)24 Jun

EDINET Filings(27)

Expand
  • IRCorrection Extraordinary Report5 Jun
  • PRSAmended Securities Registration Statement5 Jun
  • PRSSecurities registration statement25 May
  • IRExtraordinary Report25 May
  • IRExtraordinary Report12 May
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)27 Apr
  • IRExtraordinary Report15 Apr
  • IRSemi-Annual Report (2025.01.01-2025.12.31)29 Sep 2025
  • PRSAmended Securities Registration Statement5 Jun 2025
  • IRCorrection Extraordinary Report5 Jun 2025
  • PRSSecurities registration statement30 May 2025
  • IRExtraordinary Report30 May 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)27 Apr 2025
  • IRSemi-Annual Report (2024.01.01-2024.12.31)24 Sep 2024
  • PRSAmended Securities Registration Statement31 May 2024
  • IRCorrection Extraordinary Report31 May 2024
  • PRSSecurities registration statement22 May 2024
  • IRExtraordinary Report22 May 2024
  • 10-KAmended Annual Securities Report6 May 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)29 Apr 2024

News

  • Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk20 Oct
  • ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics20 Oct
  • Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System19 Oct
  • Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany19 Oct
  • Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration15 Oct
  • Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?14 Oct
  • EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing14 Oct
  • Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)11 Oct
  • 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)10 Oct
  • Press Release : Availability of the aide-mémoire for Q3 2026 results6 Oct
  • Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up5 Oct
  • As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema5 Oct
  • Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®2 Oct
  • Sanofi, Regeneron Expand Immunology Alliance With New Antibodies2 Oct
  • Regeneron And Sanofi Announce A Win-Win Collaboration Expansion1 Oct
  • Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion1 Oct
  • Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion1 Oct
  • Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion1 Oct
  • Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal1 Oct
  • Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies1 Oct

Mentions in Filings

  • … e our patent rights in the future. For example, in Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that claims to certain DNA molecules are not eligible for patenting. In Amgen Inc. v. <strong>Sanofi</strong>, the Supreme Court held that claims with functional language may face high hurdles in fulfilling the enablement requirement. Recent Federal Circuit decisions, such as Cellect v. Vidal, raise questions regarding the award …
    Lycia Therapeutics, Inc.Sanofi American Depositary Receipt·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·23 Oct
  • … isons must be interpreted with caution. As a result, conclusive cross-trial comparisons cannot be made; 1 Patient populations: Global Prevalence: Asthma Yang 2025, COPD Adeloye 2022, AD Tian 2023, US+EU5+Japan Prevalence: <strong>Sanofi</strong> Epidemiology 2023 Report; 2 Market sizes: Global Total Market Size, Asthma 2023, AD 2025 – Source: Grand View Research, COPD 2023 – Source: GlobalData; 3 Asthma and COPD Exacerbation Data: Drug Labels, Singh D et al 2024 …
    Bolt Biotherapeutics, Inc.Sanofi American Depositary Receipt·EX-99.2 - 8-K - Entry into a Material Definitive Agreement·Q4 26·23 Oct
  • … rights of patent owners in certain situations. We cannot predict how decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. For example, the U.S. Supreme Court held in Amgen v. <strong>Sanofi</strong> (2023) that a functionally claimed genus was invalid for failing to comply with the enablement requirement of the Patent Act. As such, our patent rights with functional claims may be vulnerable to third party challenges s …
    Aspen Neuroscience, Inc.Sanofi American Depositary Receipt·S-1/A - Registration statement (general form, amendment)·Q4 26·22 Oct
  • … (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre-clinical stage biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by <strong>Sanofi</strong> S.A. in March 2018) and The Medicines Company (acquired by Novartis AG in January 2020). Mr. Germano received his B.S. in Pharmacy from Albany College of Pharmacy. Our Board believes that Mr. Germano is qualified to serve …
    Eloxx Pharmaceuticals, Inc.Sanofi American Depositary Receipt·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·21 Oct
  • … (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre-clinical stage biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by <strong>Sanofi</strong> S.A. in March 2018) and The Medicines Company (acquired by Novartis AG in January 2020). Mr. Germano received his B.S. in Pharmacy from Albany College of Pharmacy. Our Board believes that Mr. Germano is qualified to serve …
    Eloxx Pharmaceuticals, Inc.Sanofi American Depositary Receipt·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·21 Oct
  • … thKline K.K. from April 2017 to February 2019. Mr. Fauchet joined GlaxoSmithKline K.K. as President & Representative Director in 2010. Previously, he served as Senior Vice President, Corporate Business Development Head of <strong>Sanofi</strong>-Aventis Group and a member of the Management Committee. Mr. Fauchet is an external director on the board of two Japanese biotech companies and a consultant for various life sciences companies. Mr. Fauchet is a graduate of …
    Rezolute, Inc.Sanofi American Depositary Receipt·DEF 14A - Definitive proxy statement·Q2 27·21 Oct

Key Stats

Trading

Px/Chg 1D$39.92 / -1.84%
Avg Volume3.41M
Beta0.28
Mkt Cap95.86B
FD Mkt Cap107.62B

Float

Shrs Out/Float2.40B / 2.17B
Short Float0.00%
Days to Cover1.22
Stock Repurchased$5.68B

Current Valuation

EV110.67B
EV/EBITDA8.77
EV/Sales2.34
P/B1.32
P/S2.02
FCF Yield1.66%
ROE10.95%
ROA6.16%
Current Ratio1.09

Dividend

Cash$2.42
Yield5.58%
Yield (TTM)5.58%

Estimates

P/E12.69
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-3.9416.1422.5325.13-142.9159.39
Price / Sales5.463.332.923.159.388.53
Price / Book Value1.631.811.641.801.601.32
Price / Free Cash Flow37.3216.2314.0823.7472.1360.40
ENTERPRISE VALUE METRICS
Enterprise Value132,921.6143,974.1131,965.2150,521.3127,479.5110,667.9
Enterprise Value / Sales6.083.553.173.4010.449.84
Enterprise Value / EBITDA22.0010.6611.5913.6433.3540.75
Enterprise Value / EBIT34.5213.8418.9620.2168.8750.74

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.5%39,175.040,561.041,618.044,286.046,716.0
Gross Income5.8%26,920.028,679.028,990.031,081.033,667.0
EBITDA2%11,538.013,510.011,390.011,033.012,479.0
EBIT-4.5%8,187.010,402.06,961.07,447.06,801.0
Net Income5.9%6,223.08,371.05,400.05,560.07,813.0
EPS (Diluted)6.5%2.493.182.152.193.20
BALANCE SHEET
Cash & ST Inv-6.7%10,098.012,736.08,710.07,927.07,657.0
Total Assets1.3%120,242.0126,722.0126,464.0132,798.0126,806.0
Total Liabilities1.8%51,211.051,570.052,111.054,941.055,096.0
Total Shareholder Equity96.7%68,681.074,784.074,040.077,507.071,376.0
CASH FLOW
Net Operating Cash Flow3.6%10,522.010,526.010,258.09,081.012,132.2
Cap Ex-67.3%-2,043.0-2,201.0-1,619.0-3,195.0-1,988.6
Free Cash Flow4.6%8,479.08,325.08,639.05,886.010,143.7

Enterprise Value Bridge

Millions EUR23 Oct '26
Price (As of 23 Oct '26)41.56
Basic Shares2,401.20
Market Cap99,781.9
Diluted Shares2,408.40
Fully Diluted Shares Outstanding2,408.40
Fully Diluted Market Cap100,081.1
+Consolidated Debt20,021.0
−In-the-Money Convertible Debt—
+Capital Leases1,802.0
+Operating Leases—
−Cash & Equivalents-5,544.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest335.0
+Pension Liabilities—
Enterprise Value114,593.9

Segment data

Revenue

by Geography

  • Reportable Geographical Zones76%
  • Europe16%
  • China5%
  • France3%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US